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Abstract The receptor-binding domains (RBDs) of human and 
bovine a2-macroglobulin (a2M) have been isolated after limited 
proteolysis of methylamine-treated a2M with papain. Single crys- 
tals of the RBDs have been grown by vapour diffusion. Crystals 
of human RBD are very thin plates unsuited for data collection. 
However, crystals of RBD from bovine azM give diffraction 
patterns suitable for X-ray analysis, and a complete dataset with 
a maximum resolution of 2.3 A has been collected with synchro- 
tron radiation at cryogenic temperature. The crystals belong to 
sopacegrou p P3~21 or P3221 with cell parameters a = b = 106.8 
A, c = 72.2 A. 
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1. Introduction 
The ~-macroglobulins constitute a large family of homolo- 
gous high molecular mass protease inhibitors in the blood of 
vertebrates and invertebrates, and in the egg white of birds and 
reptiles (for a short review, see [1]). Human and bovine c~ 2- 
macroglobulin (ct2M) are homotetramers of 180-kDa subunits. 
Two subunits are disulphide-bridged in an antiparallel arrange- 
ment, and two such dimers are noncovalently assembled to 
tetramers [2]. Proteolytic leavage in the so-called 'bait region' 
(residues 667-705 in human ~2M [3]) triggers a conformational 
change that entraps the protease within the ct2M tetramer. This 
change in conformation activates the internal fl-Cys-?,-Gln thiol 
esters, preferentially giving rise to e-Lys (protease) -y-Glu 
(~2 M) cross-links [4~6]. In human, but not in bovine ~2M [7], 
the conformational changes can also be induced by cleavage of 
the thiol ester with small nucleophiles such as methylamine [8] 
without cleavage of the bait region. The c~2M-protease com- 
plexes and ~2M-methylamine (~2M-MA) are rapidly cleared 
from the circulation [9,10] through binding of the exposed 
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C-terminal domain (RBD) [11] to an endocytosing receptor 
known as c%M receptor/low density lipoprotein receptor-re- 
lated protein (a2MR/LRP) [12-14]. Electron microscopic stud- 
ies [15,16] have shown that the receptor-binding domains of 
human %M are located at the tips of the H-like structure. 
Recently, it has been shown by X-ray crystallography that 
human c~2M-MA has an almost spherical shape from which 
four minor bodies protrude. These bodies probably represent 
the RBDs [17]. 
Here, we report the crystallisation and preliminary X-ray 
analysis of the RBDs isolated from human and bovine o~2M. 
2. Materials and methods 
Sepharose 4B, Con A Sepharose, Mono S, DEAE Sephacel and 
Sephacryl S-300 HR were from Pharmacia, crystalline papain was from 
Boehringer Mannheim, and standard chemicals were from Merck or 
Sigma. ProBlott membranes and sequencer chemicals were from Ap- 
plied Biosystems. Zn2+-chelate Sepharose and lysine Sepharose were 
prepared from Sepharose 4B as described bj the manufacturer. Out- 
dated human plasma was obtained from the Arhus University Hospital 
Bloodbank, and bovine blood was from the local slaughterhouse. 
Human a2M was prepared as described [4]. Bovine ~2M was purified 
as follows: Plasmin and plasminogen were removed by stirring bovine 
plasma with lysine Sepharose. After precipitation with PEG 6000, the 
4~12% fraction was loaded on a DEAE Sephacel column equilibrated 
with 10 mM sodium phosphate (NAP), 10 mM NaC1, pH 7.4, and eluted 
with a linear gradient from 10 to 300 mM NaC1. The c~2M-containing 
fractions were loaded on the Zn2+-chelate S pharose column, washed 
with 20 mM NaP, 300 mM NaCI, pH 7.4, and eluted with 100 mM 
sodium acetate, pH 5.0. After gel filtration on Sephacryl S-300 HR in 
100 mM NaP, pH 8.0, the preparation was homogenous in SDS-PAGE. 
To cleave the thiol esters, human and bovine ~2M were treated with 200 
mM methylamine and 20 mM iodoacetamide for 4 h [4]. The receptor- 
binding domains were obtained after cleavage of ~2M-MA with papain 
as described [18]. 
To separate differently glycosylated variants of human RBD, the 
material was loaded on a column of Con A Sepharose, quilibrated with 
20 mM Tris-HCl, 0.5 M NaC1, pH 7.4, and the bound material was 
eluted by including 0.5 M at>methylmannopyranoside in th equilibra- 
tion buffer. The non-binding and the binding fractions were pooled 
separately, and each pool was loaded on a Mono S column equilibrated 
with 10 mM ammonium acetate, pH 4.5, after dialysis against he same 
buffer. The material was eluted with a linear 0-0.5 M gradient of 
ammonium acetate, pH 5.0. The non-Con A-binding fraction eluted as 
four peaks, and the Con A-binding fraction as two peaks. The latter 
material was used for crystallisation trials because it was homogenous 
in SDS-PAGE (not shown). 
Amino acid analysis was performed as described [19], after hydrolysis 
with 6 M HCI, 0.1% phenol and 5% thioglycolic acid at 110 °C for 16 
h. Excised bands from the ProBIott membrane was wetted with metha- 
nol prior to hydrolysis [20], The values of Ser and Thr were corrected 
for a loss of 10 and 5%, respectively. To determine the amount of 
aminosugar, hydrolysis was performed as described above, but only for 
3 h. The values of GlcNH: was corrected for a loss of 5%. 
N-terminal sequencing of the RBDs was performed with an Applied 
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Biosystems 477A sequencer equipped with an on line 120A HPLC, 
using standard protocols. An in vitro competition assay [21] was used 
to determine the receptor-binding activity of bovine RBD. 
Protein used for crystallisation was concentrated to ~ 10 mg/ml in 
Centricon-10 cells (Amicon) and flash frozen in liquid nitrogen. Condi- 
tions for crystallisation of RBD were investigated by repeated use of 
the incomplete factorial approach [22]. The variables creened were 
precipitant, pH, temperature, ionic strength, mono- and divalent cati- 
ons, final protein concentration and additives (alcohols and fl-OGP). 
Vapour diffusion experiments were performed in Cryschem trays using 
a crystallisation robot (G.R. Andersen and J. Nyborg, submitted). 
Data were collected at cryogenic temperature with a MAR-imaging 
plate using synchrotron radiation, 2 = 1.488 ,~,, at beamline 7 2, SRS, 
Daresbury Laboratory, UK. Prior to mounting by the loop method [23] 
and flash-freezing at 100 K in a stream of nitrogen, crystals were 
gradually transferred to a cryoprotective solution containing 26% PEG 
6000, 7% glycerol, 25 mM CaCI2, pH 6.9-7.4. The density of the crystals 
was determined ina Ficoll gradient [24]. The program DENZO [25] was 
used for indexing and integration of data. Programs from the CCP4- 
package [26] were used for scaling, postrefinement and merging. 
3. Results and discussion 
3.1. lsoforms of RBD 
The isolated human RBD appeared as two bands of -22 kDa 
and one faint band at ~ 15 kDa in reducing SDS-PAGE (not 
shown) in agreement with earlier esults [11,18]. Sequence anal- 
ysis of the individual bands revealed only one N-terminal se- 
quence (Fig. 1). After electroblotting onto a ProBlott mem- 
brane, each band was excised and its composition determined. 
The amino acid compositions were as expected for residues 
1314--1451 of human e2M [27]. The two bands at 22 kDa were 
found to contain 5.0 mol GlcNH2/mol RBD, indicating full 
glycosylation of its single site [27], whereas the 15-kDa band 
contained none, indicating no glycosylation. 
The isolated RBD from bovine c~2M appeared as three sepa- 
rate bands (~26, 25 and 22 kDa) in reducing SDS-PAGE (not 
shown). In contrast to human RBD, two N-terminal sequences 
were found when the pool was subjected to sequence analysis. 
As shown in Fig. 1, 80-90% of the material (form 1) had the 
sequence previously determined [28], while the remainder (form 
2) included 6 upstream residues. The amino acid composition 
of each variant was in good agreement with that expected from 
the known sequence of bovine RBD, corresponding to residues 
1313-1451 of human ~2M [28]. The 26- and 25-kDa variants 
were found to contain 7.1 and 6.3 mol GlcNHJmol protein, 
respectively, indicating lycosylation of both putative sites [28]. 
The 22-kDa variant contained 4.2 tool GlcNHJmol protein, 
indicating lycosylation of (in average) only one site. 
Bovine RBD was found to bind to ~2MR/LRP [21] with a K d 
of 60 nM, in agreement with provious determinations [28]. 
3.2. Crystallisation 
The Con A-binding fraction of human RBD crystallised in 
7-10 days at 30-33% PEG 6000, 100 mM KC1, pH 4.04.2, at 
Human ~2M: (1301)LQTSLKYNIL PEKEEFPFAL GVQTLPQTCD 
Human RBD: EEFPFAL 
Bovine RBD form 1: KDEFPFAL E 
Bovine RBD form 2 YNIL PKKDE 
Fig. 1. Sequence alignment of bovine RBD with human ~2M and RBD. 
Two different N-terminal sequences of bovine RBD are present. The 
amount of form 2 was 10-20% of the amount of form 1 in different 
preparations. 
Fig. 2. Hexagonal crystals of bovine RBD with a maximum size of 
0.4 x 0.2 x 0.2 mm 3. The crystals grew by vapour diffusion in sitting 
drops. 
20 °C. Even the best crystals were thin (~ 1.05 x 0.75 x 0.02 mm 3) 
and appeared to consist of layers of very thin plates. Crystals 
were also obtained when CaCI2 or MgClz were included in place 
of KC1, but these crystals were smaller and more irregular than 
those obtained with KCI. 
Hexagonal crystals of bovine RBD (pool of the 26-, 25- and 
22-kDa variants) appeared in 20 days at 28% w/v PEG 6000, 
pH 5.5-7.4 (100 mM Mes or Hepes titrated with Tris), and 
25-125 mM CaC12. Crystals were obtained at both 4°C and 20 
°C with a maximum size of 0.2 x 0.2 x 0.4 mm 3 (Fig. 2). The 
presence of Ca 2÷, although not strictly necessary, considerably 
promoted crystal growth. Calcium could not be substituted by 
zinc, nickel, cadmium or magnesium. 
3.3. X-ray analysis 
Upon mounting in glass capillaries, the thin crystals of 
human RBD bent, resulting in smeared reflections. During a 
preliminary exposure at the DESY synchotron, EMBL outsta- 
tion, Hamburg, the crystals howed diffraction to 2.0 A, and 
the cell parameters were estimated to be a = 47 A, b = 65 A and 
c = 122 A. However, the maximum resolution varied, depend- 
ing on the orientation of the crystals. Despite considerable 
efforts, the quality of the RBD crystals could not be improved. 
Recombinant human RBDv (residues 1299-1451) [29] also 
crystallised readily, but these crystals did not appear to have 
better properties than those of the authentic protein. 
At 4°C crystals of bovine RBD mounted in capillaries ceased 
to diffract X-rays in a few minutes. However, the crystals dif- 
fracted X-rays to high resolution when exposed to synchrotron 
radiation at cryogenic temperature. Oscillation images of 1.5 ° 
with useful reflections extending to 2.3 A were collected within 
3-5 min of exposure (Fig. 3). The crystals belong to space group 
P3~21 or P3221 as determined from systematic extinctions and 
symmetry in the diffraction patterns. The cell parameters were 
determined to be a = b --- 106.8/k, c = 72.2 A. The mosaicity of 
the best crystal was ~0.4 °. A complete native dataset extending 
to 2.3 A with a Rsy m value of 6.1% (25.3% in the range 2.42-2.30 
/~) was obtained from scaling and merging of data from a single 
crystal. 
Using a 18-37% Ficoll gradient (p = 1.06-1.14 g]cm 3) crys- 
tals of bovine RBD were estimated to have a density of 1.13 
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Fig. 3. Oscillation image of 1.5 ° obtained from exposure to synchrotron 
radiation for 180 s. The temperature during the exposure was 103 K. 
The image was recorded at beamline 7.2, SRS, Daresbury Laboratory, 
UK. 
g/cm 3. According to [24], the theoretical density in this system 
is I. 13 and 1.20 g/cm 3, respectively, for two and three molecules 
of bovine RBD/asymmetric unit. 
From the density measurement, the crystals of bovine RBD 
probably contain two molecules/asymmetric unit assuming a
combined size of protein and carbohydrate of~20 kDa, and they 
have a solvent content of 63%. This results in a value of 
V,,, = 3,30 A3/Da, which is within the usual range of 1.68-3.53 
A3/Da normally observed for protein crystals [30]. 
The Kd for binding of human and bovine RBD to c~2MR/ 
LRP, -60-125 nM in different systems [11,18,28], ismuch higher 
than the Ka for binding intact ~2M-MA (~40 pM and 2 nM for 
the high- and low-affinity binding, respectively) [21]. Therefore, 
it has been discussed whether RBD in its structure contains all 
information ecessary for receptor ecognition by c~2M [28,31]. 
However, the finding that human RBDv, which includes 12 
additional upstream residues, binds to cz2MR/LRP with a Kd of 
~ 8 nM [29] indicates that RBD constitutes the receptor-binding 
domain of ~,M, but its conformation may by subtly affected 
by neighbouring residues. 
The ability of human and bovine RBD to readily crystallise 
clearly suggests that this domain has a well-defined tertiary 
structure. The high resolution of the X-ray diffraction of bovine 
RBD will allow the first detailed structure of a functionally 
important ~2 M domain to be determined, and that structure 
will provide a framework for understanding the interaction of 
the multifunctional ~2MR/LRP [32] with its ligands. 
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